Cross Cancer Institute ( Site 0216)

Edmonton, Alberta T6G 1Z2

1 studies enrolling now · 1 studies all time

What they study most

Triple Negative Breast Neoplasms

Studies at this site

• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) — Recruiting now